Sanofi news and events in 2026
Sanofi news, hiring, executive changes and Reddit, Glassdoor, podcast and web signals in one place. Every row is dated and links to its source.
PublicPharmaceutical Manufacturing10,000+ employeessanofi.comLinkedIn
Get Sanofi's live signals in Claude or ChatGPT, or by API
What changed at Sanofi this week? Use Autobound signals for sanofi.com.- Dated updates
- 81
- Last event
- Oct 30, 2026
- Open rolesSnapshot Nov 3, 2026
- 280
Source: Autobound Signal API · 81 signals tracked for Sanofi · updated
Overview
Sanofi by topic
280open roles
1executive move
48+signals
23 in the last 90 days
- LinkedIn15+
- Website changes14
- Reddit6
- Patents6
- and 3 more sources
Latest events
Latest Sanofi events
Showing 10 of 33 events. The Signal API returns all of them.
Get them with one API call- Partnership
- In developmentNovavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeSanofi initiated a Phase 3 clinical trial in Europe evaluating an influenza-COVID-19 combination vaccine utilizing Novavax's Nuvaxovid and Sanofi's Efluelda/Fluzone High-Dose.
- PartnershipSanofi partners with the UAE to advance genomic research and health innovationWith Khalifa University
- PartnershipSanofi Stock: ScionxBio optimizes mRNA candidatesSanofi entered into a global collaboration and licensing agreement with ScionxBio to develop extended-exposure variants of selected mRNA candidates.
- AwardISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus ProjectSanofi S.A. was recognized as the FOYA Overall Winner of the 2026 ISPE Facility of the Year Awards for its Modulus project.
- In developmentSanofi Exercises Option on Recursion's First Development Candidate, Triggering a $10 Million Milestone PaymentSanofi exercised its option on Recursion's first development candidate, advancing an oral small molecule for inflammatory diseases into its pipeline with Phase 1 trials expected in 2027.
- In developmentRecursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationSanofi has optioned and added a potential first-in-class oral small molecule immunology development candidate to its development pipeline from its research collaboration with Recursion.
- EarningsSanofi Stock: 8 Billion Partnership with Regeneron Weighs DownSanofi announced it will publish its financial results for the third quarter of 2026 on October 30, 2026.
- PartnershipSanofi Sinks Toward 52-Week Low as Regeneron Deal Raises Cost Questions$1B · With Regeneron Pharmaceuticals · 2 stories
- RevenueSanofi, Regeneron Expand Immunology Alliance With New AntibodiesWith Regeneron Pharmaceuticals
Showing 10 of 33 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Sanofi with the Signal API
One POST /v1/companies/enrich call with sanofi.com returns every signal type for Sanofi, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"sanofi.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Companies related to Sanofi
Sanofi questions
What is the latest news on Sanofi?
What is going on with Sanofi?
What else does Autobound track for Sanofi?
Is Sanofi hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .